BioSpace News Archive

Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced two podium presentations and a live case transmission featuring the company’s Lumivascular technology at the Leipzig Interventional Course (LINC) 2022.

Stimwave Technologies Incorporated and its subsidiary, Stimwave LLC, a leading provider of neurostimulation devices offering chronic pain relief, announced that it has reached an agreement to sell substantially all of its assets to Kennedy Lewis Management LP or its affiliate.

Pliant Therapeutics, Inc. announced that the Company will present two scientific posters at the International Liver Congress™ 2022 of the European Association for the Study of the Liver, taking place June 22-26, 2022, in London, United Kingdom.

Arcellx, Inc. announced the pricing of an upsized underwritten follow-on offering of 7,000,000 shares of common stock at a price to the public of $16.00 per share.

NuGen Medical Devices Inc., a leader in needle-free drug delivery, in collaboration with Unifire Inc., a wholly owned subsidiary of Mission Ready Solutions submitted on June14th, 2022, an application to the U.S. Food and Drug Administration for Emergency Use Authorization of NuGen reusable needle-free jet injector systems.

I-Mab today announced two assets the Company has licensed from partner MorphoSys AG (FSE: MOR; NASDAQ: MOR), felzartamab (also known as TJ202/MOR202) and TJ210 (also known as MOR210), are advancing globally through new license agreements.

Fibronostics , a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding.

Affini-T Therapeutics, Inc., and Metagenomi, Inc., today announced a partnership to enable Affini-T’s next generation ex vivo T cell receptor (TCR) cell therapies for solid tumor patients using Metagenomi’s novel proprietary gene editing systems.

ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled ‘Therapeutic vaccination with CLB-3000 in a mouse model of chronic Hepatitis B induces anti-HBs responses associated with functional cure’ was accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2022.

The Lung Transplant Foundation (LTF), a non-profit organization dedicated to creating a world where all lung transplant patients live long, healthy lives, announced today it will host an externally-led patient-focused drug development meeting with the U.S. Food and Drug Administration (FDA) on Wednesday, June 22, 2022 from 10:00 a.m. – 3:00 p.m. ET in Washington DC.